---
title: "Pluri regains Nasdaq audit committee compliance"
url: "https://aibio.space/news/pluri-regains-nasdaq-audit-committee-compliance-after-naming/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-09-12"
section: "Listings"
tickers: "NASDAQ:PLUR"
source: "https://www.sec.gov/Archives/edgar/data/1158780/000121390025087052/ea0257121-8k_pluri.htm"
summary: "Nasdaq confirmed the matter is closed after Pluri elected Eitan Ajchenbaum as an independent director and Audit Committee chair. The gap began after the Ju"
---

By the aibio.space news desk.

Sources

- [Pluri Inc. 8-K (2025-09-12)](https://www.sec.gov/Archives/edgar/data/1158780/000121390025087052/ea0257121-8k_pluri.htm)

[PLUR](https://aibio.space/companies/pluri/)

2025-09-12

# Pluri regains Nasdaq audit committee compliance after naming independent director

Tickers [PLUR](https://aibio.space/companies/pluri/)

Nasdaq confirmed the matter is closed after Pluri elected Eitan Ajchenbaum as an independent director and Audit Committee chair. The gap began after the June 30, 2025 annual meeting.

## Key facts

- **Company**: Pluri Inc. (NASDAQ: PLUR)

- **News type**: Listings

- **Primary source**: [Pluri Inc. 8-K (2025-09-12)](https://www.sec.gov/Archives/edgar/data/1158780/000121390025087052/ea0257121-8k_pluri.htm)

*The facade of a neoclassical court building at dusk. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Pluri Inc. said Nasdaq has confirmed it again meets the exchange's audit committee rules, closing a listing issue that opened this summer.

On July 2, 2025, Pluri told the Listing Qualifications Department of The Nasdaq Stock Market LLC that its Audit Committee no longer met the independence requirements of Nasdaq Listing Rule 5605(c)(2)(A). The problem followed the non-election of a director at the company's annual shareholders meeting on June 30, 2025.

Nasdaq then sent Pluri a letter of non-compliance and granted it a cure period under Listing Rule 5605(c)(4). A cure period is the time a company is given to fix a rule breach before the exchange takes further action.

On September 11, 2025, Pluri announced the election of Eitan Ajchenbaum as an independent director. He also joined the Audit Committee as a member and its Chairman.

After that announcement, Pluri received a letter from Nasdaq confirming that it had regained compliance with the audit committee requirement and that the matter is now closed. The company disclosed the letter in a filing dated September 12, 2025. Its common shares trade on The Nasdaq Capital Market under the symbol PLUR.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

PLUR

Pluri Inc.

NASDAQ · Israel

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/pluri-regains-nasdaq-audit-committee-compliance-after-naming/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Pluri regains Nasdaq audit committee compliance", 2025-09-12, https://aibio.space/news/pluri-regains-nasdaq-audit-committee-compliance-after-naming/